Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2025)

Ascentage Pharma Group International (AAPG) has 3 years of Total Non-Current Liabilities data on file, last reported at $139.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 15.16% year-over-year to $139.0 million; the trailing twelve-month figure through Dec 2025 stood at $139.0 million (down 15.16% YoY), and the FY2025 full-year result was $141.0 million, down 12.56% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $139.0 million, down from $163.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $207.7 million in Q4 2023 and bottomed at $139.0 million in Q4 2025.
• The 3-year median for Total Non-Current Liabilities is $163.9 million (2024), against an average of $170.2 million.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities fell 21.11%; it then decreased 15.16% in 2025.
• A 3-year view of Total Non-Current Liabilities shows it stood at $207.7 million in 2023, then retreated by 21.11% to $163.9 million in 2024, then fell by 15.16% to $139.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $139.0 million (Q4 2025), $163.9 million (Q4 2024), and $207.7 million (Q4 2023), per Business Quant data.

Peer Comparison